SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-017412
Filing Date
2022-11-10
Accepted
2022-11-10 16:08:53
Documents
14
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nbrv-20221110x8k.htm   iXBRL 8-K 37036
2 EX-99.1 nbrv-20221110xex99d1.htm EX-99.1 254867
3 GRAPHIC nbrv-20221110xex99d1001.jpg GRAPHIC 7097
  Complete submission text file 0001558370-22-017412.txt   439494

Data Files

Seq Description Document Type Size
4 EX-101.SCH nbrv-20221110.xsd EX-101.SCH 3111
5 EX-101.LAB nbrv-20221110_lab.xml EX-101.LAB 15879
6 EX-101.PRE nbrv-20221110_pre.xml EX-101.PRE 10210
8 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20221110x8k_htm.xml XML 4894
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 221377172
SIC: 2834 Pharmaceutical Preparations